Therefore, the aim of the present study was to determine whether potential anti-miR-155 therapy in CLL, which may restore/improve BTLA expression in the B cell population, increasing their activation threshold, could pose a risk in terms of its potential simultaneous effect on the T cell population when administered systemically. This evidence concerns the gene BTLA and B-cell chronic lymphocytic leukemia.